Xue-Ning Duan
Overview
Explore the profile of Xue-Ning Duan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
132
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zheng C, Yu L, Jia H, Cui S, Tian F, Fan Z, et al.
Front Public Health
. 2022 Jan;
9:767151.
PMID: 34976926
The aim of this study was to evaluate the relationship between lifestyle habits and health-related quality of life (HRQoL) among different ages who were initially diagnosed with breast cancer (within...
2.
Wang F, Duan X, Ling R, Yu Z
Chin Med J (Engl)
. 2021 Jun;
134(14):1655-1657.
PMID: 34116529
No abstract available.
3.
Ye J, Guo B, Liu Q, Ma F, Liu H, Wu Q, et al.
Chin Med J (Engl)
. 2021 Apr;
134(8):886-894.
PMID: 33813512
No abstract available.
4.
Yu L, Liu L, Xiang Y, Wang F, Zhou F, Huang S, et al.
Cancer Med
. 2021 Mar;
10(8):2752-2762.
PMID: 33734613
Background: X-ray repair cross-complementary 5 (XRCC5) and 6 (XRCC6) are critical for DNA repair. Few studies have assessed their association with breast cancer risk, and related gene-environment interactions remain poorly...
5.
Yang S, Xiang H, Xin L, Zhang H, Zhang S, Cheng Y, et al.
Chin Med J (Engl)
. 2021 Feb;
134(3):318-325.
PMID: 33522727
Background: Methylene blue is the most commonly used tracer for sentinel lymph node (SLN) biopsy (SLNB) in China. This study aimed to investigate the feasibility of clinical application of SLNB...
6.
Bai Y, Gao G, Zhang H, Zhang S, Liu Y, Duan X, et al.
Chin Med J (Engl)
. 2020 Feb;
133(5):552-560.
PMID: 32044815
Background: After neoadjuvant chemotherapy (NAC), non-pathological complete response of breast cancer patients can benefit from tailored adjuvant chemotherapy. However, it is difficult to select patients with poorer prognosis for additional...
7.
Xiang H, Liu Y, Zhang H, Zhang S, Xin L, Xu L, et al.
Chin Med J (Engl)
. 2019 Dec;
132(24):2914-2919.
PMID: 31809316
Background: The results of the Trial Assigning IndividuaLized Options for Treatment (TAILORx) suggested that approximately 70% of T1-2N0M0, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer patients...
8.
Liu L, Wang F, Cui S, Tian F, Fan Z, Geng C, et al.
Oncotarget
. 2017 Dec;
8(57):97217-97230.
PMID: 29228605
This study aimed to investigate risk factors associated with breast cancer among Han Chinese women in northern and eastern China. A matched case-control study involving 1489 patients with breast cancer...
9.
Xu L, Li J, Ye J, Duan X, Cheng Y, Xin L, et al.
Chin Med J (Engl)
. 2017 Aug;
130(16):1945-1952.
PMID: 28776547
Background: Current understanding of tumor biology suggests that breast cancer is a group of diseases with different intrinsic molecular subtypes. Anatomic staging system alone is insufficient to provide future outcome...
10.
Guo M, Duan X, Cui S, Tian F, Cao X, Geng C, et al.
PLoS One
. 2015 Jun;
10(6):e0129246.
PMID: 26070203
The level of total adiponectin, a mixture of different adiponectin forms, has been reported associated with breast cancer risk with inconsistent results. Whether the different forms play different roles in...